By Benjamin Chiou
Date: Monday 23 Feb 2026
(Sharecast News) - US pharma group Merck & Co is set to spin off its oncology operations in an effort to keep its wider healthcare businesses immune from a forthcoming patent cliff for its blockbuster Keytruda drug.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 115.68 |
| Change Today | $ 1.50 |
| % Change | 1.31 % |
| 52 Week High | $122.46 |
| 52 Week Low | $73.47 |
| Volume | 9,092,520 |
| Shares Issued | 2,474.63m |
| Market Cap | $286,265m |
| RiskGrade | 92 |
| Strong Buy | 8 |
| Buy | 10 |
| Neutral | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 16:02 | 1,332,226 @ $115.68 |
| 16:00 | 142 @ $115.69 |
| 16:00 | 300 @ $115.68 |
| 16:00 | 200 @ $115.68 |
| 15:59 | 200 @ $115.68 |
You are here: research